Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin.
Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin.
复制标题
细胞减少手术后的原发性肿瘤位置和结局和结直肠内腹膜转移的腹膜内化学疗法。
DOI：
10.1245/s10434-020-08993-7
复制
发表时间：
2021-03
影响因子：
3.7
通讯作者：
Nash GM
中科院分区：
文献类型：
--
作者：
Adileh M;Yuval JB;Walch HS;Chatila WK;Yaeger R;Garcia-Aguilar J;Schultz N;Paty PB;Cercek A;Nash GM
本研究的目的是评估结直肠癌腹膜转移（pmCRC）患者接受细胞减灭术和腹腔化疗（CRS/IPC）的结果与原发肿瘤的位置。区域治疗包括肿瘤细胞减灭术和腹腔化疗与pmCRC患者生存率的提高相关。原发肿瘤的位置已被证明是转移患者的预后。对2010年至2017年接受完全细胞减灭术和腹腔化疗的所有患者进行了回顾性分析，检查了患者和肿瘤特征、总体和无复发生存期、复发模式和肿瘤突变特征。93例患者纳入研究：49例（53%）为右侧原发性肿瘤，44例（47%）为左侧原发性肿瘤。右侧肿瘤患者的无复发生存期明显较短（中位数：6.3个月[95% CI，4.7-8.1] vs 12.3个月[95% CI，3.6-21.7]; P = 0.02）和总生存期（中位数，36.6个月[95% CI，26.4-46.9] vs 83.3个月[95% CI 44.2-122.4]; P = 0.03）。BRAF和KRAS突变在右侧肿瘤中更常见，APC和TP 53突变在染色体更不稳定的左侧肿瘤中更常见。BRAF突变与早期复发相关。肿瘤侧性是CRS/IPC后肿瘤结局的预测因子。当咨询患者预期结果时，以及选择或分层pmCRC患者进行区域治疗临床试验时，应考虑肿瘤的侧性和分子特征。
The aim of this study was to evaluate outcomes in patients with peritoneal metastasis of colorectal cancer (pmCRC) who underwent cytoreductive surgery and intraperitoneal chemotherapy (CRS/IPC) in relation to the location of the primary tumor. Regional therapy including cytoreductive surgery and intraperitoneal chemotherapy has been associated with improved survival in patients with pmCRC. Location of the primary tumor has been shown to be prognostic in patients with metastasis. A retrospective review was performed for all patients who underwent complete cytoreduction and intraperitoneal chemotherapy from 2010 to 2017, examining patient and tumor characteristics, overall and recurrence-free survival, recurrence patterns, and tumor mutational profiles. Ninety-three patients were included in the study: 49 (53%) with a right-sided and 44 (47%) with a left-sided primary tumor. Patients with a right-sided tumor had significantly shorter recurrence-free survival (median, 6.3 months [95% CI, 4.7–8.1] vs 12.3 months [95% CI, 3.6–21.7]; P = 0.02) and overall survival (median, 36.6 months [95% CI, 26.4–46.9] vs 83.3 months [95% CI 44.2–122.4]; P = 0.03). BRAF and KRAS mutations were more frequent in right-sided tumors, and APC and TP53 mutations were more frequent in left-sided tumors, which were more chromosomally instable. BRAF mutations were associated with early recurrence. Tumor sidedness is a predictor of oncological outcomes after CRS/IPC. Tumor sidedness and molecular characteristics should be considered when counseling patients regarding expected outcomes and when selecting or stratifying pmCRC patients for clinical trials of regional therapy.
登录
查看更多内容
癌症基因组地图集中的致癌信号通路。
影响因子：
64.5
作者：
Sanchez-Vega F;Mina M;Armenia J;Chatila WK;Luna A;La KC;Dimitriadoy S;Liu DL;Kantheti HS;Saghafinia S;Chakravarty D;Daian F;Gao Q;Bailey MH;Liang WW;Foltz SM;Shmulevich I;Ding L;Heins Z;Ochoa A;Gross B;Gao J;Zhang H;Kundra R;Kandoth C;Bahceci I;Dervishi L;Dogrusoz U;Zhou W;Shen H;Laird PW;Way GP;Greene CS;Liang H;Xiao Y;Wang C;Iavarone A;Berger AH;Bivona TG;Lazar AJ;Hammer GD;Giordano T;Kwong LN;McArthur G;Huang C;Tward AD;Frederick MJ;McCormick F;Meyerson M;Cancer Genome Atlas Research Network;Van Allen EM;Cherniack AD;Ciriello G;Sander C;Schultz N
通讯作者：
Schultz N
影响因子：
45.3
作者：
Elias, Dominique;Gilly, Francois;Glehen, Olivier
通讯作者：
Glehen, Olivier
影响因子：
3.7
作者：
Ha, Gi Won;Kim, Jong Hun;Lee, Min Ro
通讯作者：
Lee, Min Ro
影响因子：
11.5
作者：
Sinicrope, Frank A.;Mahoney, Michelle R.;Alberts, Steven R.
通讯作者：
Alberts, Steven R.
影响因子：
3.8
作者：
Dupre, Aurelien;Malik, Hassan Z.;Poston, Graeme J.
通讯作者：
Poston, Graeme J.